{
    "clinical_study": {
        "@rank": "151433", 
        "acronym": "SIGNATURE", 
        "arm_group": {
            "arm_group_label": "LDE225", 
            "arm_group_type": "Experimental", 
            "description": "LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this signal seeking study is to determine whether treatment with LDE225\n      demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic\n      malignancies to warrant further study"
        }, 
        "brief_title": "LDE225 for Patients With PTCH1 or SMO Mutated Tumors", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "PTCH1 or SMO Activated Solid and Hematologic Tumors", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient has confirmed diagnosis of a select solid tumor (except medulloblastoma,\n             basal cell carcinoma and pancreatic adenocarcinoma) or hematological malignancy\n             (except CML, ALL and AML).\n\n          -  Patient has pre-identified tumor with a PTCH1 or SMO mutation.\n\n          -  Patient has received at least one prior treatment for recurrent, metastatic and /or\n             locally advanced disease and for whom no standard therapy options are anticipated to\n             result in a durable remission.\n\n          -  Patient has progressive and measurable disease as per RECIST 1.1. or other\n             appropriate hematological guidelines.\n\n          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1\n\n        Exclusion Criteria:\n\n          -  Patients has received prior treatment with LDE225.\n\n          -  Patients has neuromuscular disorders associated with elevated CK (i.e. inflammatory\n             myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular\n             atrophy) or are on concomitant treatment with drugs that are recognized to cause\n             rhabdomyolysis\n\n          -  Patients has primary CNS tumor or CNS tumor involvement\n\n          -  Patient has received chemotherapy or anticancer therapy \u2264 4 weeks prior to starting\n             study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002689", 
            "org_study_id": "CLDE225XUS20"
        }, 
        "intervention": {
            "arm_group_label": "LDE225", 
            "description": "LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule", 
            "intervention_name": "LDE225", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Solid tumor malignancy,", 
            "hematologic malignancy,", 
            "mutation, translocations,", 
            "signature,", 
            "PTCH1,", 
            "SMO,", 
            "LDE225,", 
            "endometrial cancer,", 
            "colon cancer,", 
            "bladder,", 
            "NSCLC"
        ], 
        "lastchanged_date": "February 16, 2014", 
        "link": {
            "url": "http://www.signaturetrial.com"
        }, 
        "location": [
            {
                "contact": {
                    "phone": "832-824-5383"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77024"
                    }, 
                    "name": "Oncology Consultants Oncology Group"
                }, 
                "investigator": {
                    "last_name": "Julio Peguero", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "713-745-0147"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3)"
                }, 
                "investigator": {
                    "last_name": "Sarina Piha-Paul", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 5 LDE225 for Patients With PTCH1 or SMO Mutated Tumors", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-855-744-6727"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical benefit rate for patients with solid tumors will be assessed using RECIST 1.1 and will include responses of CR or PR or SD. For hematologic tumors other appropriate hematological response criteria will apply", 
            "measure": "Clinical benefit rate associated with LDE225 treatment", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002689"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall Response (OR) of Partial Response (PR) or greater based on local investigator assessment. For patients with solid tumors, the assessment criteria will be RECIST 1.1 and will include responses of CR and/or PR. For hematologic tumors other appropriate hematological response criteria will apply", 
                "measure": "Overall Response (OR) of Partial Response (PR) or greater", 
                "safety_issue": "No", 
                "time_frame": "Baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months"
            }, 
            {
                "description": "Progression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause", 
                "measure": "Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks until death, assessed up to 24 months"
            }, 
            {
                "description": "Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks until death, assessed up to 36 months"
            }, 
            {
                "description": "Duration of response (DOR) is defined as time from the first documented response to the date first documented disease progression or relapse or death due to any cause", 
                "measure": "Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months"
            }, 
            {
                "description": "Safety and tolerability will be based on the frequency of adverse events and on the number of laboratory values that fall outside of pre-determined ranges. Other safety data (e.g., electrocardiogram, vital signs) will be considered as appropriate", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "baseline up to 30 days after last study treatment"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}